Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 3 Neoplasm Metastasis 2 Nasopharyngeal Carcinoma 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Peritoneal Neoplasms 1 Osteosarcoma 1 Liver, Cancer of, Primary Resectable 1 Hepatocellular Carcinoma Resectable 1 Head and Neck Neoplasms 1 Carcinoma, Hepatocellular 1 Advanced Gastric Cancer 1 Acute Toxic Effects 1

Interventions

Sorafenib 202 lenvatinib 129 Bevacizumab 124 Nivolumab 85 pembrolizumab 72 atezolizumab 72 Radiosurgery 71 durvalumab 63 Oxaliplatin 59 sintilimab 57 Fluorouracil 54 Doxorubicin 44 tislelizumab 43 apatinib 43 Leucovorin 40 tremelimumab 37 camrelizumab 37 Radiofrequency Ablation 37 Radiotherapy 36 Magnetic Resonance Spectroscopy 32 Capecitabine 30 regorafenib 29 Folfox protocol 29 Cisplatin 28 cabozantinib 26 Hepatectomy 26 Gemcitabine 26 Cyclophosphamide 26 Ipilimumab 25 toripalimab 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Hepatocellular × lobaplatin × Clear all

NCT02301091 2016-04-14

CORTT

Sun Yat-sen University

Phase 3 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡